For example, Tiplaxtinin not only synergized with anti-PD-L1 in prolonging survival in a mouse model of melanoma 45, but also played synergistic effects with cisplatin in inhibiting ESCC in vitro and in vivo46-47. This evidence concerns the gene CD274 and melanoma.